Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Autoimmune Disorders

  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 76 articles:
HTML format

Single Articles

    July 2021
  1. HAWKINS P, Chawke L, Cormican L, Wikenheiser-Brokamp KA, et al
    Autoimmune pulmonary alveolar proteinosis: a discrepancy between symptoms and CT findings.
    Lancet. 2021;398:e7.

    June 2021
  2. MCGINLEY MP, Cohen JA
    Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
    Lancet. 2021 Jun 24. pii: S0140-6736(21)00244.
    PubMed     Abstract available

  3. TSAGKAS C, Schafer S, Baumgartner A, Muller J, et al
    Syndrome of inappropriate antidiuretic hormone secretion and hypothalamic hypocortisolism in neuromyelitis optica.
    Lancet. 2021;397:2194.

    May 2021
  4. ROVIN BH, Teng YKO, Ginzler EM, Arriens C, et al
    Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Lancet. 2021 May 7. pii: S0140-6736(21)00578.
    PubMed     Abstract available

  5. MOK CC
    A new old treatment for lupus nephritis.
    Lancet. 2021 May 7. pii: S0140-6736(21)00663.

    April 2021
  6. BAYAS A, Menacher M, Christ M, Behrens L, et al
    Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination.
    Lancet. 2021 Apr 14. pii: S0140-6736(21)00872.

    February 2021
  7. SHAHRIZAILA N, Lehmann HC, Kuwabara S
    Guillain-Barre syndrome.
    Lancet. 2021 Feb 26. pii: S0140-6736(21)00517.
    PubMed     Abstract available

  8. LAMBRECHTS RA, Uyttenboogaart M, Drost G
    A vertebral artery halo sign indicates giant cell arteritis affecting the posterior circulation of the brain.
    Lancet. 2021;397:e6.

    January 2021
  9. BERGENSTAL RM, Nimri R, Beck RW, Criego A, et al
    A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.
    Lancet. 2021;397:208-219.
    PubMed     Abstract available

    December 2020
  10. LLEO A, Wang GQ, Gershwin ME, Hirschfield GM, et al
    Primary biliary cholangitis.
    Lancet. 2020;396:1915-1926.
    PubMed     Abstract available

    November 2020
  11. DIAS L, Araujo R
    Ice pack test in myasthenia gravis: a cool investigation at the bedside.
    Lancet. 2020;396:e82.

    October 2020
  12. HABIB SM, Vermeer MH
    A baby with red plaques on the face and a first-degree heart block: neonatal lupus.
    Lancet. 2020;396:1432.

  13. UDOMKARNJANANUN S, Puapatanakul P, Praditpornsilpa K
    Relapsing polychondritis associated with pauci-immune crescentic glomerulonephritis.
    Lancet. 2020;396:e63.

    August 2020
  14. FREITAS PFS, Oliveira JM, Kater CE
    Crisis? What crisis? Abdominal pain and darkening skin in Addison's disease.
    Lancet. 2020;396:498.

    May 2020
    Interferon beta-1b for COVID-19.
    Lancet. 2020 May 8. pii: S0140-6736(20)31101.

    March 2020
  16. NEHRING P, Przybylkowski A
    Think twice before operating on a pancreatic mass: could it be IgG4-related disease?
    Lancet. 2020;395:816.

    February 2020
  17. SEN A, Jette N, Husain M, Sander JW, et al
    Epilepsy in older people.
    Lancet. 2020;395:735-748.
    PubMed     Abstract available

    January 2020
  18. GARRETT C, Ismail K
    Forgotten: mental health interventions in type 1 diabetes.
    Lancet. 2020;395:115.

    November 2019
    JAK inhibitors: promising for a wider spectrum of autoimmune diseases?
    Lancet. 2019 Nov 11. pii: S0140-6736(19)32681.

    October 2019
  20. BRUINSTROOP E, Cairo I, Drillenburg P, van Dam PS, et al
    Hypothyroidism to Graves' disease and late appearance of pretibial myxoedema.
    Lancet. 2019;394:1364.

  21. SILBERMANN E, Bourdette D
    A new era for neuromyelitis optica spectrum disorder.
    Lancet. 2019;394:1304-1305.

  22. CREE BAC, Bennett JL, Kim HJ, Weinshenker BG, et al
    Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
    Lancet. 2019;394:1352-1363.
    PubMed     Abstract available

    September 2019
  23. BECK RW, Bergenstal RM, Laffel LM, Pickup JC, et al
    Advances in technology for management of type 1 diabetes.
    Lancet. 2019 Sep 13. pii: S0140-6736(19)31142.
    PubMed     Abstract available

  24. DAYAN CM, Korah M, Tatovic D, Bundy BN, et al
    Changing the landscape for type 1 diabetes: the first step to prevention.
    Lancet. 2019 Sep 13. pii: S0140-6736(19)32127.
    PubMed     Abstract available

  25. VANTYGHEM MC, de Koning EJP, Pattou F, Rickels MR, et al
    Advances in beta-cell replacement therapy for the treatment of type 1 diabetes.
    Lancet. 2019 Sep 13. pii: S0140-6736(19)31334.
    PubMed     Abstract available

  26. SCHMIDT E, Kasperkiewicz M, Joly P
    Lancet. 2019;394:882-894.
    PubMed     Abstract available

    June 2019
  27. DORNER T, Furie R
    Novel paradigms in systemic lupus erythematosus.
    Lancet. 2019;393:2344-2358.
    PubMed     Abstract available

  28. DURCAN L, O'Dwyer T, Petri M
    Management strategies and future directions for systemic lupus erythematosus in adults.
    Lancet. 2019;393:2332-2343.
    PubMed     Abstract available

    May 2019
  29. LUO J, Gonsalves G, Greene J
    Insulin for all: treatment activism and the global diabetes crisis.
    Lancet. 2019;393:2116-2117.

    April 2019
  30. ELAGHA A, Mohsen A
    Cardiac MRI clinches diagnosis of Libman-Sacks endocarditis.
    Lancet. 2019;393:e39.

  31. MCCALL B
    Alemtuzumab to be restricted pending review, says EMA.
    Lancet. 2019;393:1683.

    March 2019
  32. COSTACOU T, Guo J, Miller RG, Orchard TJ, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:985.

  33. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes - Authors' reply.
    Lancet. 2019;393:985-986.

  34. SNAITH JR, Holmes-Walker DJ, Girgis CM, Greenfield JR, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:984-985.

    February 2019
  35. YUAN K, Huang G, Sang X, Xu A, et al
    Baricitinib for systemic lupus erythematosus.
    Lancet. 2019;393:402.

  36. WALLACE DJ, Furie RA, Tanaka Y, de Bono S, et al
    Baricitinib for systemic lupus erythematosus - Authors' reply.
    Lancet. 2019;393:402-403.

    January 2019
  37. POWER SP, O'Mahony D
    Diffuse large vessel giant cell arteritis found by (18)Fluorodeoxyglucose PET/CT imaging.
    Lancet. 2019;393:349.

    December 2018
    Type 2 diabetes: the urgent need to protect young people.
    Lancet. 2018;392:2325.

    October 2018
    Ustekinumab: a promising new drug for SLE?
    Lancet. 2018;392:1284-1286.

  40. GALDERISI A, Sherr JL
    Enlarging the loop: closed-loop insulin delivery for type 1 diabetes.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32329.

  41. TAUSCHMANN M, Thabit H, Bally L, Allen JM, et al
    Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)31947.
    PubMed     Abstract available

    September 2018
  42. VAN VOLLENHOVEN RF, Hahn BH, Tsokos GC, Wagner CL, et al
    Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
    Lancet. 2018 Sep 21. pii: S0140-6736(18)32167.
    PubMed     Abstract available

  43. LEBWOHL B, Sanders DS, Green PH
    Coeliac disease and dermatitis herpetiformis - Authors' reply.
    Lancet. 2018;392:917.

  44. RODRIGUES F, Bachmeyer C
    Coeliac disease and dermatitis herpetiformis.
    Lancet. 2018;392:916.

  45. CAIO G, De Giorgio R, Volta U
    Coeliac disease and dermatitis herpetiformis.
    Lancet. 2018;392:916-917.

  46. FLUME PA, Chalmers JD, Olivier KN
    Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.
    Lancet. 2018;392:880-890.
    PubMed     Abstract available

  47. PERL A, Lai ZW, Kelly R, Faraone SV, et al
    Sirolimus for systemic lupus erythematosus - Authors' reply.
    Lancet. 2018;392:734.

  48. HU HQ, Lee FJ, Garsia R
    Sirolimus for systemic lupus erythematosus.
    Lancet. 2018;392:733-734.

    August 2018
  49. BASINA M, Maahs DM
    Age at type 1 diabetes onset: a new risk factor and call for focused treatment.
    Lancet. 2018;392:453-454.

  50. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.
    Lancet. 2018;392:477-486.
    PubMed     Abstract available

    July 2018
  51. WALLACE DJ, Furie RA, Tanaka Y, Kalunian KC, et al
    Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet. 2018;392:222-231.
    PubMed     Abstract available

  52. MUCKE J, Schneider M
    Baricitinib for systemic lupus erythematosus.
    Lancet. 2018;392:190-192.

    June 2018
  53. XIAO F, Tian X, Wang XF
    Antiphospholipid syndrome causing reversible internal carotid artery thrombosis.
    Lancet. 2018;391:2641.

  54. DIMEGLIO LA, Evans-Molina C, Oram RA
    Type 1 diabetes.
    Lancet. 2018;391:2449-2462.
    PubMed     Abstract available

    March 2018
  55. CHATTERJEE S, Khunti K, Davies MJ
    Type 2 diabetes - Authors' reply.
    Lancet. 2018;391:1262.

  56. TATE AR
    Type 2 diabetes.
    Lancet. 2018;391:1261-1262.

  57. BOUSSAGEON R, Roustit M, Gueyffier F, Tudrej BV, et al
    Type 2 diabetes.
    Lancet. 2018;391:1261.

  58. METZ LM, Liu WQ
    Effective treatment of progressive MS remains elusive.
    Lancet. 2018;391:1239-1240.

  59. KAPPOS L, Bar-Or A, Cree BAC, Fox RJ, et al
    Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
    Lancet. 2018 Mar 22. pii: S0140-6736(18)30475.
    PubMed     Abstract available

  60. THOMPSON AJ, Baranzini SE, Geurts J, Hemmer B, et al
    Multiple sclerosis.
    Lancet. 2018 Mar 22. pii: S0140-6736(18)30481.
    PubMed     Abstract available

    End of the road for daclizumab in multiple sclerosis.
    Lancet. 2018;391:1000.

  62. LAI ZW, Kelly R, Winans T, Marchena I, et al
    Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.
    Lancet. 2018 Mar 15. pii: S0140-6736(18)30485.
    PubMed     Abstract available

    CD8 T cells and mTOR: new concepts and targets for systemic lupus erythematous.
    Lancet. 2018 Mar 15. pii: S0140-6736(18)30544.

    February 2018
    Continuous glucose monitoring: transforming diabetes management step by step.
    Lancet. 2018 Feb 15. pii: S0140-6736(18)30290.

  65. HEINEMANN L, Freckmann G, Ehrmann D, Faber-Heinemann G, et al
    Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.
    Lancet. 2018 Feb 15. pii: S0140-6736(18)30297.
    PubMed     Abstract available

    January 2018
    Type 1 diabetes.
    Lancet. 2018;391:195.

    December 2017
  67. TSUDA K, Tanimoto T, Mori J, Kosugi K, et al
    Targeted-release budesonide therapy for IgA nephropathy.
    Lancet. 2017;390:2625.

  68. FELLSTROM B, Barratt J, Floge J, Jardine A, et al
    Targeted-release budesonide therapy for IgA nephropathy - Authors' reply.
    Lancet. 2017;390:2625-2626.

    October 2017
  69. GREEN AJ, Gelfand JM, Cree BA, Bevan C, et al
    Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.
    Lancet. 2017 Oct 10. pii: S0140-6736(17)32346.
    PubMed     Abstract available

  70. RUBIN R
    Mary Crow: leader in research on systemic lupus erythematosus.
    Lancet. 2017;390:1636.

    September 2017
  71. GARG SK, Polsky S
    Continuous glucose monitoring in pregnant women with type 1 diabetes.
    Lancet. 2017 Sep 14. pii: S0140-6736(17)32449.

  72. FEIG DS, Donovan LE, Corcoy R, Murphy KE, et al
    Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial.
    Lancet. 2017 Sep 14. pii: S0140-6736(17)32400.
    PubMed     Abstract available

    March 2017
  73. WYATT RJ
    Are we ready for targeted therapy for IgA nephropathy?
    Lancet. 2017 Mar 28. pii: S0140-6736(17)30820.

  74. FELLSTROM BC, Barratt J, Cook H, Coppo R, et al
    Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
    Lancet. 2017 Mar 28. pii: S0140-6736(17)30550.
    PubMed     Abstract available

    December 2016
  75. EL-KHATIB FH, Balliro C, Hillard MA, Magyar KL, et al
    Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.
    Lancet. 2016 Dec 20. pii: S0140-6736(16)32567.
    PubMed     Abstract available

    September 2016
  76. BOLINDER J, Antuna R, Geelhoed-Duijvestijn P, Kroger J, et al
    Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial.
    Lancet. 2016 Sep 9. pii: S0140-6736(16)31535.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.